Hair cloning updates, with potential costs ranging from $200,000 to $350,000. Clinical trials may start in 2020, and some hope for cheaper options in Turkey or China.
PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.
A 33-year-old is using topical minoxidil, oral finasteride (1mg), a derma pen, and 0.05% tretinoin on the hairline to treat hair loss, showing progress after 2 months. They apply tretinoin in the evening with minoxidil and use a derma pen once a week at 1.5mm.
CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.
RootBioTec, a basil hairy root extract, claims to reduce hair loss by 31% in two months by inhibiting 5α reductase II and stimulating hair follicles. There is limited independent information available about its effectiveness.
The conversation is about hair loss treatment progress using a combination of 0.1% finasteride, 0.025% tretinoin solution, and 2.5mg oral minoxidil. Users express positive reactions and hope for similar results.
The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.
People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.
The conversation discusses the fluctuation of testosterone levels in men under 40 and the difference between serum DHT and scalp DHT. It also mentions that DHT levels are higher on Dutasteride than on Finasteride, which is unusual.
The user has been using dutasteride, minoxidil with tretinoin, and ketoconazole shampoo for hair loss but hasn't seen improvement in temple areas. Suggestions include trying microneedling with minoxidil or considering a hair transplant, though temple transplants can be challenging.
The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.
27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.
Excess Vitamin A and topical retinoids can cause diffuse hair shedding. The user suspects their chronic telogen effluvium may be linked to using adapalene, a topical retinoid.
A user shared their two-year progress using 1mg finasteride, topical minoxidil, and occasional microneedling, noting no significant changes but a halt in hair loss progression. They recently started oral minoxidil and are considering a hair transplant.
A 26-year-old male experienced hair thinning since age 18 and tried various treatments, including topical minoxidil, oral finasteride, and a hair transplant. He is currently using topical finasteride, minoxidil, tretinoin, hydrocortisone, and oral dutasteride, and is satisfied with the results 6.5 months post-transplant.
A 31-year-old man shared his 2-year experience using finasteride and minoxidil after a hair transplant on the front and mid scalp, noting improvement but still having a thin crown. He recently started dermastamping, plans to use ketoconazole shampoo, and uses hair fibers for extra confidence at events.
An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.
The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.
A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.
A 15-year-old is seeking advice on preventing hair loss, identified as Norwood level 2, and wants tips for growing long hair. They have consulted a trichologist who recommended specific shampoos.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
Pyrilutamide's 0.5% solution showed minimal improvement, while the 1% solution appears more promising but costly. The user is currently using finasteride and oral minoxidil and considering adding Pyrilutamide if effective and affordable.
Low oxytocin levels in hair are linked to reduced empathy and may affect hair growth. Cinnamic acid can promote hair growth by activating oxytocin receptors.
The conversation discusses a 20-year-old transgender female's one-year experience with hair loss treatments, including Estradiol HRT, oral Finasteride, Bicalutamide, and Cyproterone. Specific treatments used for hair loss are oral Finasteride and potentially Estradiol as part of hormone replacement therapy.
User can't find 2% keto shampoo in their area and asks about ketoconazole BP20. Replies confirm that 20mg/ml means 2% ketoconazole and BP stands for British Pharmacopoeia, ensuring purity and quality standards.
Treatments for hair loss, including topical dutasteride minoxidil, tretonin, dermarolling, serioxyl, and redensyl over a period of 3 months; switching from RU58841 to pyrilutamide was suggested with potentially less risk of systemic side effects; and encouragement to not give up hope.